PDS Biotechnology published Phase 2 VERSATILE-002 results for PDS0101 plus pembrolizumab, reporting 39.3 months median overall survival in the overall CPS ≥1 population. The publication matters to investors because PDS Biotech says it is pursuing partnerships for PDS0101 while prioritizing PDS0301 in metastatic colorectal cancer.
Key Highlights
- Objective response reached 36% for the CPS ≥1 population, with complete responses recorded under investigator review.
- VERSATILE-002 reported median overall survival of 39.3 months in the overall CPS ≥1 population.
- Objective response rate was 36% under investigator review and 34% under central review.
- Grade 3 or higher treatment-related adverse events occurred in 13.8% of patients, with no Grade 5 treatment-related adverse events reported.
PDS Biotechnology Corp. (NASDAQ: PDSB) is a Pharmaceuticals: Major company. Results from its VERSATILE-002 Phase 2 trial of PDS0101 with pembrolizumab showed median overall survival of 39.3 months in the overall CPS ≥1 population. PDS Biotech said it will prioritize PDS0301 in metastatic colorectal cancer while pursuing a Partnership strategy for PDS0101.
Response and
Safety Measures The objective response rate for CPS ≥1 was 36% under investigator review and 34% under central review. The cited standard-of-care pembrolizumab result for the same population was 19%, while the cited median overall survival result for standard pembrolizumab or pembrolizumab plus chemotherapy was 17.9 months. Grade 3 or higher treatment-related adverse events occurred at a 13.8% rate, compared with 17% in the cited standard-of-care safety result, and no Grade 5 treatment-related adverse events were reported. The company said no head-to-head trials had been performed.
FAQs
Q: What did PDS Biotechnology’s VERSATILE-002 study evaluate?
A: The VERSATILE-002 Phase 2 trial evaluated PDS0101 with pembrolizumab. Results appeared in JAMA Oncology.
Q: What was the PDS0101 overall survival result?
A: Median overall survival reached 39.3 months in the overall CPS ≥1 population. The cited standard-of-care pembrolizumab or pembrolizumab-plus-chemotherapy result was 17.9 months.
Q: What is PDS Biotechnology’s next development focus?
A: PDS Biotech’s next development focus is PDS0301 in metastatic colorectal cancer. The company is also pursuing a partnership strategy for PDS0101.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.